nodes	percent_of_prediction	percent_of_DWPC	metapath
Gemifloxacin—Mental disorder—Sorafenib—liver cancer	0.00427	0.00428	CcSEcCtD
Gemifloxacin—Dysgeusia—Sorafenib—liver cancer	0.00415	0.00417	CcSEcCtD
Gemifloxacin—Muscle spasms—Sorafenib—liver cancer	0.00408	0.00409	CcSEcCtD
Gemifloxacin—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00394	0.00396	CcSEcCtD
Gemifloxacin—Anaemia—Sorafenib—liver cancer	0.00392	0.00393	CcSEcCtD
Gemifloxacin—Glossitis—Epirubicin—liver cancer	0.00389	0.00391	CcSEcCtD
Gemifloxacin—Syncope—Sorafenib—liver cancer	0.0038	0.00382	CcSEcCtD
Gemifloxacin—Leukopenia—Sorafenib—liver cancer	0.00379	0.00381	CcSEcCtD
Gemifloxacin—Blood bilirubin increased—Epirubicin—liver cancer	0.00379	0.00381	CcSEcCtD
Gemifloxacin—Loss of consciousness—Sorafenib—liver cancer	0.00373	0.00374	CcSEcCtD
Gemifloxacin—Coordination abnormal—Epirubicin—liver cancer	0.00365	0.00367	CcSEcCtD
Gemifloxacin—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.00365	0.00366	CcSEcCtD
Gemifloxacin—Arthralgia—Sorafenib—liver cancer	0.00361	0.00362	CcSEcCtD
Gemifloxacin—Myalgia—Sorafenib—liver cancer	0.00361	0.00362	CcSEcCtD
Gemifloxacin—Glossitis—Doxorubicin—liver cancer	0.0036	0.00361	CcSEcCtD
Gemifloxacin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00358	0.0036	CcSEcCtD
Gemifloxacin—Phosphatase alkaline increased—Epirubicin—liver cancer	0.00358	0.0036	CcSEcCtD
Gemifloxacin—Vaginal inflammation—Epirubicin—liver cancer	0.00358	0.0036	CcSEcCtD
Gemifloxacin—Abnormal dreams—Epirubicin—liver cancer	0.00354	0.00356	CcSEcCtD
Gemifloxacin—Dry mouth—Sorafenib—liver cancer	0.00353	0.00354	CcSEcCtD
Gemifloxacin—Eructation—Epirubicin—liver cancer	0.00352	0.00354	CcSEcCtD
Gemifloxacin—Blood bilirubin increased—Doxorubicin—liver cancer	0.00351	0.00352	CcSEcCtD
Gemifloxacin—Anaphylactic shock—Sorafenib—liver cancer	0.00346	0.00347	CcSEcCtD
Gemifloxacin—Candida infection—Epirubicin—liver cancer	0.00342	0.00344	CcSEcCtD
Gemifloxacin—Skin exfoliation—Epirubicin—liver cancer	0.00342	0.00344	CcSEcCtD
Gemifloxacin—Shock—Sorafenib—liver cancer	0.0034	0.00342	CcSEcCtD
Gemifloxacin—Nervous system disorder—Sorafenib—liver cancer	0.00339	0.00341	CcSEcCtD
Gemifloxacin—Thrombocytopenia—Sorafenib—liver cancer	0.00339	0.0034	CcSEcCtD
Gemifloxacin—Blood urea increased—Epirubicin—liver cancer	0.00338	0.0034	CcSEcCtD
Gemifloxacin—Vaginal infection—Epirubicin—liver cancer	0.00338	0.0034	CcSEcCtD
Gemifloxacin—Coordination abnormal—Doxorubicin—liver cancer	0.00338	0.00339	CcSEcCtD
Gemifloxacin—Skin disorder—Sorafenib—liver cancer	0.00336	0.00337	CcSEcCtD
Gemifloxacin—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.00332	0.00333	CcSEcCtD
Gemifloxacin—Vaginal inflammation—Doxorubicin—liver cancer	0.00332	0.00333	CcSEcCtD
Gemifloxacin—Anorexia—Sorafenib—liver cancer	0.0033	0.00331	CcSEcCtD
Gemifloxacin—Cramps of lower extremities—Epirubicin—liver cancer	0.00329	0.00331	CcSEcCtD
Gemifloxacin—Abnormal dreams—Doxorubicin—liver cancer	0.00328	0.00329	CcSEcCtD
Gemifloxacin—Eructation—Doxorubicin—liver cancer	0.00326	0.00327	CcSEcCtD
Gemifloxacin—Mouth ulceration—Epirubicin—liver cancer	0.00324	0.00325	CcSEcCtD
Gemifloxacin—Candida infection—Doxorubicin—liver cancer	0.00317	0.00318	CcSEcCtD
Gemifloxacin—Skin exfoliation—Doxorubicin—liver cancer	0.00317	0.00318	CcSEcCtD
Gemifloxacin—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00315	0.00317	CcSEcCtD
Gemifloxacin—Blood urea increased—Doxorubicin—liver cancer	0.00313	0.00314	CcSEcCtD
Gemifloxacin—Vaginal infection—Doxorubicin—liver cancer	0.00313	0.00314	CcSEcCtD
Gemifloxacin—Abnormal vision—Epirubicin—liver cancer	0.00313	0.00314	CcSEcCtD
Gemifloxacin—Dyspnoea—Sorafenib—liver cancer	0.00308	0.0031	CcSEcCtD
Gemifloxacin—Cramps of lower extremities—Doxorubicin—liver cancer	0.00305	0.00306	CcSEcCtD
Gemifloxacin—Dyspepsia—Sorafenib—liver cancer	0.00305	0.00306	CcSEcCtD
Gemifloxacin—Decreased appetite—Sorafenib—liver cancer	0.00301	0.00302	CcSEcCtD
Gemifloxacin—Mouth ulceration—Doxorubicin—liver cancer	0.003	0.00301	CcSEcCtD
Gemifloxacin—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00299	0.003	CcSEcCtD
Gemifloxacin—Gastrointestinal disorder—Sorafenib—liver cancer	0.00299	0.003	CcSEcCtD
Gemifloxacin—Fatigue—Sorafenib—liver cancer	0.00298	0.003	CcSEcCtD
Gemifloxacin—Photosensitivity—Epirubicin—liver cancer	0.00296	0.00298	CcSEcCtD
Gemifloxacin—Pain—Sorafenib—liver cancer	0.00296	0.00297	CcSEcCtD
Gemifloxacin—Constipation—Sorafenib—liver cancer	0.00296	0.00297	CcSEcCtD
Gemifloxacin—Eczema—Epirubicin—liver cancer	0.00289	0.00291	CcSEcCtD
Gemifloxacin—Abnormal vision—Doxorubicin—liver cancer	0.00289	0.0029	CcSEcCtD
Gemifloxacin—Gastrointestinal pain—Sorafenib—liver cancer	0.00283	0.00284	CcSEcCtD
Gemifloxacin—Renal failure acute—Epirubicin—liver cancer	0.00282	0.00283	CcSEcCtD
Gemifloxacin—Hot flush—Epirubicin—liver cancer	0.00278	0.00279	CcSEcCtD
Gemifloxacin—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00277	0.00278	CcSEcCtD
Gemifloxacin—Menopausal symptoms—Epirubicin—liver cancer	0.00276	0.00277	CcSEcCtD
Gemifloxacin—Urticaria—Sorafenib—liver cancer	0.00275	0.00276	CcSEcCtD
Gemifloxacin—Photosensitivity—Doxorubicin—liver cancer	0.00274	0.00275	CcSEcCtD
Gemifloxacin—Abdominal pain—Sorafenib—liver cancer	0.00273	0.00275	CcSEcCtD
Gemifloxacin—Body temperature increased—Sorafenib—liver cancer	0.00273	0.00275	CcSEcCtD
Gemifloxacin—Eczema—Doxorubicin—liver cancer	0.00268	0.00269	CcSEcCtD
Gemifloxacin—Hyponatraemia—Epirubicin—liver cancer	0.00261	0.00262	CcSEcCtD
Gemifloxacin—Renal failure acute—Doxorubicin—liver cancer	0.00261	0.00262	CcSEcCtD
Gemifloxacin—Hot flush—Doxorubicin—liver cancer	0.00257	0.00258	CcSEcCtD
Gemifloxacin—Gatifloxacin—ALB—liver cancer	0.00257	0.599	CrCbGaD
Gemifloxacin—Menopausal symptoms—Doxorubicin—liver cancer	0.00255	0.00256	CcSEcCtD
Gemifloxacin—Face oedema—Epirubicin—liver cancer	0.00251	0.00252	CcSEcCtD
Gemifloxacin—Asthenia—Sorafenib—liver cancer	0.00248	0.00249	CcSEcCtD
Gemifloxacin—Pruritus—Sorafenib—liver cancer	0.00245	0.00246	CcSEcCtD
Gemifloxacin—Blood creatinine increased—Epirubicin—liver cancer	0.00244	0.00245	CcSEcCtD
Gemifloxacin—Hyponatraemia—Doxorubicin—liver cancer	0.00242	0.00243	CcSEcCtD
Gemifloxacin—Diarrhoea—Sorafenib—liver cancer	0.00237	0.00238	CcSEcCtD
Gemifloxacin—Breast disorder—Epirubicin—liver cancer	0.00235	0.00236	CcSEcCtD
Gemifloxacin—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00234	0.00235	CcSEcCtD
Gemifloxacin—Face oedema—Doxorubicin—liver cancer	0.00232	0.00233	CcSEcCtD
Gemifloxacin—Gastritis—Epirubicin—liver cancer	0.0023	0.00231	CcSEcCtD
Gemifloxacin—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00229	0.0023	CcSEcCtD
Gemifloxacin—Dizziness—Sorafenib—liver cancer	0.00229	0.0023	CcSEcCtD
Gemifloxacin—Blood creatinine increased—Doxorubicin—liver cancer	0.00226	0.00226	CcSEcCtD
Gemifloxacin—Dysphagia—Epirubicin—liver cancer	0.00225	0.00226	CcSEcCtD
Gemifloxacin—Eosinophilia—Epirubicin—liver cancer	0.00223	0.00224	CcSEcCtD
Gemifloxacin—Pancreatitis—Epirubicin—liver cancer	0.0022	0.00221	CcSEcCtD
Gemifloxacin—Vomiting—Sorafenib—liver cancer	0.0022	0.00221	CcSEcCtD
Gemifloxacin—Rash—Sorafenib—liver cancer	0.00218	0.00219	CcSEcCtD
Gemifloxacin—Dermatitis—Sorafenib—liver cancer	0.00218	0.00219	CcSEcCtD
Gemifloxacin—Breast disorder—Doxorubicin—liver cancer	0.00218	0.00218	CcSEcCtD
Gemifloxacin—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00217	0.00218	CcSEcCtD
Gemifloxacin—Headache—Sorafenib—liver cancer	0.00217	0.00218	CcSEcCtD
Gemifloxacin—Gastritis—Doxorubicin—liver cancer	0.00213	0.00214	CcSEcCtD
Gemifloxacin—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00212	0.00213	CcSEcCtD
Gemifloxacin—Dysphagia—Doxorubicin—liver cancer	0.00208	0.00209	CcSEcCtD
Gemifloxacin—Eosinophilia—Doxorubicin—liver cancer	0.00206	0.00207	CcSEcCtD
Gemifloxacin—Nausea—Sorafenib—liver cancer	0.00206	0.00206	CcSEcCtD
Gemifloxacin—Photosensitivity reaction—Epirubicin—liver cancer	0.00205	0.00206	CcSEcCtD
Gemifloxacin—Pancreatitis—Doxorubicin—liver cancer	0.00204	0.00205	CcSEcCtD
Gemifloxacin—Hyperglycaemia—Epirubicin—liver cancer	0.00203	0.00204	CcSEcCtD
Gemifloxacin—Pneumonia—Epirubicin—liver cancer	0.00202	0.00203	CcSEcCtD
Gemifloxacin—Infestation NOS—Epirubicin—liver cancer	0.002	0.00201	CcSEcCtD
Gemifloxacin—Infestation—Epirubicin—liver cancer	0.002	0.00201	CcSEcCtD
Gemifloxacin—Renal failure—Epirubicin—liver cancer	0.00197	0.00198	CcSEcCtD
Gemifloxacin—Neuropathy peripheral—Epirubicin—liver cancer	0.00197	0.00197	CcSEcCtD
Gemifloxacin—Stomatitis—Epirubicin—liver cancer	0.00195	0.00196	CcSEcCtD
Gemifloxacin—Haematuria—Epirubicin—liver cancer	0.00191	0.00192	CcSEcCtD
Gemifloxacin—Photosensitivity reaction—Doxorubicin—liver cancer	0.0019	0.00191	CcSEcCtD
Gemifloxacin—Hepatobiliary disease—Epirubicin—liver cancer	0.0019	0.0019	CcSEcCtD
Gemifloxacin—Hyperglycaemia—Doxorubicin—liver cancer	0.00188	0.00188	CcSEcCtD
Gemifloxacin—Agranulocytosis—Epirubicin—liver cancer	0.00187	0.00188	CcSEcCtD
Gemifloxacin—Pneumonia—Doxorubicin—liver cancer	0.00187	0.00187	CcSEcCtD
Gemifloxacin—Infestation NOS—Doxorubicin—liver cancer	0.00185	0.00186	CcSEcCtD
Gemifloxacin—Infestation—Doxorubicin—liver cancer	0.00185	0.00186	CcSEcCtD
Gemifloxacin—Renal failure—Doxorubicin—liver cancer	0.00182	0.00183	CcSEcCtD
Gemifloxacin—Neuropathy peripheral—Doxorubicin—liver cancer	0.00182	0.00183	CcSEcCtD
Gemifloxacin—Haemoglobin—Epirubicin—liver cancer	0.00181	0.00182	CcSEcCtD
Gemifloxacin—Stomatitis—Doxorubicin—liver cancer	0.00181	0.00182	CcSEcCtD
Gemifloxacin—Haemorrhage—Epirubicin—liver cancer	0.0018	0.00181	CcSEcCtD
Gemifloxacin—Pharyngitis—Epirubicin—liver cancer	0.00179	0.00179	CcSEcCtD
Gemifloxacin—Urinary tract disorder—Epirubicin—liver cancer	0.00178	0.00178	CcSEcCtD
Gemifloxacin—Oedema peripheral—Epirubicin—liver cancer	0.00177	0.00178	CcSEcCtD
Gemifloxacin—Haematuria—Doxorubicin—liver cancer	0.00177	0.00178	CcSEcCtD
Gemifloxacin—Connective tissue disorder—Epirubicin—liver cancer	0.00177	0.00178	CcSEcCtD
Gemifloxacin—Urethral disorder—Epirubicin—liver cancer	0.00176	0.00177	CcSEcCtD
Gemifloxacin—Hepatobiliary disease—Doxorubicin—liver cancer	0.00175	0.00176	CcSEcCtD
Gemifloxacin—Visual impairment—Epirubicin—liver cancer	0.00173	0.00174	CcSEcCtD
Gemifloxacin—Agranulocytosis—Doxorubicin—liver cancer	0.00173	0.00174	CcSEcCtD
Gemifloxacin—Norfloxacin—CYP1A1—liver cancer	0.00172	0.401	CrCbGaD
Gemifloxacin—Erythema multiforme—Epirubicin—liver cancer	0.0017	0.00171	CcSEcCtD
Gemifloxacin—Eye disorder—Epirubicin—liver cancer	0.00168	0.00169	CcSEcCtD
Gemifloxacin—Haemoglobin—Doxorubicin—liver cancer	0.00167	0.00168	CcSEcCtD
Gemifloxacin—Flushing—Epirubicin—liver cancer	0.00167	0.00168	CcSEcCtD
Gemifloxacin—Cardiac disorder—Epirubicin—liver cancer	0.00167	0.00168	CcSEcCtD
Gemifloxacin—Haemorrhage—Doxorubicin—liver cancer	0.00167	0.00167	CcSEcCtD
Gemifloxacin—Pharyngitis—Doxorubicin—liver cancer	0.00165	0.00166	CcSEcCtD
Gemifloxacin—Urinary tract disorder—Doxorubicin—liver cancer	0.00164	0.00165	CcSEcCtD
Gemifloxacin—Oedema peripheral—Doxorubicin—liver cancer	0.00164	0.00165	CcSEcCtD
Gemifloxacin—Connective tissue disorder—Doxorubicin—liver cancer	0.00164	0.00164	CcSEcCtD
Gemifloxacin—Angiopathy—Epirubicin—liver cancer	0.00163	0.00164	CcSEcCtD
Gemifloxacin—Urethral disorder—Doxorubicin—liver cancer	0.00163	0.00164	CcSEcCtD
Gemifloxacin—Immune system disorder—Epirubicin—liver cancer	0.00163	0.00163	CcSEcCtD
Gemifloxacin—Mediastinal disorder—Epirubicin—liver cancer	0.00162	0.00163	CcSEcCtD
Gemifloxacin—Visual impairment—Doxorubicin—liver cancer	0.0016	0.00161	CcSEcCtD
Gemifloxacin—Mental disorder—Epirubicin—liver cancer	0.00158	0.00158	CcSEcCtD
Gemifloxacin—Erythema multiforme—Doxorubicin—liver cancer	0.00157	0.00158	CcSEcCtD
Gemifloxacin—Eye disorder—Doxorubicin—liver cancer	0.00156	0.00156	CcSEcCtD
Gemifloxacin—Cardiac disorder—Doxorubicin—liver cancer	0.00155	0.00155	CcSEcCtD
Gemifloxacin—Flushing—Doxorubicin—liver cancer	0.00155	0.00155	CcSEcCtD
Gemifloxacin—Flatulence—Epirubicin—liver cancer	0.00154	0.00155	CcSEcCtD
Gemifloxacin—Tension—Epirubicin—liver cancer	0.00154	0.00154	CcSEcCtD
Gemifloxacin—Dysgeusia—Epirubicin—liver cancer	0.00153	0.00154	CcSEcCtD
Gemifloxacin—Nervousness—Epirubicin—liver cancer	0.00152	0.00153	CcSEcCtD
Gemifloxacin—Back pain—Epirubicin—liver cancer	0.00152	0.00152	CcSEcCtD
Gemifloxacin—Angiopathy—Doxorubicin—liver cancer	0.00151	0.00152	CcSEcCtD
Gemifloxacin—Muscle spasms—Epirubicin—liver cancer	0.00151	0.00151	CcSEcCtD
Gemifloxacin—Immune system disorder—Doxorubicin—liver cancer	0.0015	0.00151	CcSEcCtD
Gemifloxacin—Mediastinal disorder—Doxorubicin—liver cancer	0.0015	0.00151	CcSEcCtD
Gemifloxacin—Mental disorder—Doxorubicin—liver cancer	0.00146	0.00147	CcSEcCtD
Gemifloxacin—Anaemia—Epirubicin—liver cancer	0.00145	0.00145	CcSEcCtD
Gemifloxacin—Flatulence—Doxorubicin—liver cancer	0.00143	0.00143	CcSEcCtD
Gemifloxacin—Tension—Doxorubicin—liver cancer	0.00142	0.00143	CcSEcCtD
Gemifloxacin—Dysgeusia—Doxorubicin—liver cancer	0.00142	0.00143	CcSEcCtD
Gemifloxacin—Nervousness—Doxorubicin—liver cancer	0.00141	0.00141	CcSEcCtD
Gemifloxacin—Vertigo—Epirubicin—liver cancer	0.00141	0.00141	CcSEcCtD
Gemifloxacin—Syncope—Epirubicin—liver cancer	0.0014	0.00141	CcSEcCtD
Gemifloxacin—Leukopenia—Epirubicin—liver cancer	0.0014	0.00141	CcSEcCtD
Gemifloxacin—Back pain—Doxorubicin—liver cancer	0.0014	0.00141	CcSEcCtD
Gemifloxacin—Muscle spasms—Doxorubicin—liver cancer	0.00139	0.0014	CcSEcCtD
Gemifloxacin—Palpitations—Epirubicin—liver cancer	0.00138	0.00139	CcSEcCtD
Gemifloxacin—Loss of consciousness—Epirubicin—liver cancer	0.00138	0.00138	CcSEcCtD
Gemifloxacin—Anaemia—Doxorubicin—liver cancer	0.00134	0.00135	CcSEcCtD
Gemifloxacin—Arthralgia—Epirubicin—liver cancer	0.00133	0.00134	CcSEcCtD
Gemifloxacin—Myalgia—Epirubicin—liver cancer	0.00133	0.00134	CcSEcCtD
Gemifloxacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00132	0.00133	CcSEcCtD
Gemifloxacin—Dry mouth—Epirubicin—liver cancer	0.0013	0.00131	CcSEcCtD
Gemifloxacin—Vertigo—Doxorubicin—liver cancer	0.0013	0.00131	CcSEcCtD
Gemifloxacin—Syncope—Doxorubicin—liver cancer	0.0013	0.00131	CcSEcCtD
Gemifloxacin—Leukopenia—Doxorubicin—liver cancer	0.0013	0.0013	CcSEcCtD
Gemifloxacin—Palpitations—Doxorubicin—liver cancer	0.00128	0.00129	CcSEcCtD
Gemifloxacin—Oedema—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Gemifloxacin—Anaphylactic shock—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Gemifloxacin—Loss of consciousness—Doxorubicin—liver cancer	0.00127	0.00128	CcSEcCtD
Gemifloxacin—Shock—Epirubicin—liver cancer	0.00126	0.00126	CcSEcCtD
Gemifloxacin—Nervous system disorder—Epirubicin—liver cancer	0.00125	0.00126	CcSEcCtD
Gemifloxacin—Thrombocytopenia—Epirubicin—liver cancer	0.00125	0.00126	CcSEcCtD
Gemifloxacin—Tachycardia—Epirubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Gemifloxacin—Skin disorder—Epirubicin—liver cancer	0.00124	0.00125	CcSEcCtD
Gemifloxacin—Hyperhidrosis—Epirubicin—liver cancer	0.00124	0.00124	CcSEcCtD
Gemifloxacin—Arthralgia—Doxorubicin—liver cancer	0.00123	0.00124	CcSEcCtD
Gemifloxacin—Myalgia—Doxorubicin—liver cancer	0.00123	0.00124	CcSEcCtD
Gemifloxacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00123	0.00123	CcSEcCtD
Gemifloxacin—Anorexia—Epirubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Gemifloxacin—Dry mouth—Doxorubicin—liver cancer	0.00121	0.00121	CcSEcCtD
Gemifloxacin—Oedema—Doxorubicin—liver cancer	0.00118	0.00119	CcSEcCtD
Gemifloxacin—Anaphylactic shock—Doxorubicin—liver cancer	0.00118	0.00119	CcSEcCtD
Gemifloxacin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00116	0.00117	CcSEcCtD
Gemifloxacin—Shock—Doxorubicin—liver cancer	0.00116	0.00117	CcSEcCtD
Gemifloxacin—Nervous system disorder—Doxorubicin—liver cancer	0.00116	0.00117	CcSEcCtD
Gemifloxacin—Thrombocytopenia—Doxorubicin—liver cancer	0.00116	0.00116	CcSEcCtD
Gemifloxacin—Insomnia—Epirubicin—liver cancer	0.00116	0.00116	CcSEcCtD
Gemifloxacin—Tachycardia—Doxorubicin—liver cancer	0.00115	0.00116	CcSEcCtD
Gemifloxacin—Skin disorder—Doxorubicin—liver cancer	0.00115	0.00115	CcSEcCtD
Gemifloxacin—Hyperhidrosis—Doxorubicin—liver cancer	0.00114	0.00115	CcSEcCtD
Gemifloxacin—Dyspnoea—Epirubicin—liver cancer	0.00114	0.00114	CcSEcCtD
Gemifloxacin—Somnolence—Epirubicin—liver cancer	0.00114	0.00114	CcSEcCtD
Gemifloxacin—Anorexia—Doxorubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Gemifloxacin—Dyspepsia—Epirubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Gemifloxacin—Decreased appetite—Epirubicin—liver cancer	0.00111	0.00112	CcSEcCtD
Gemifloxacin—Gastrointestinal disorder—Epirubicin—liver cancer	0.0011	0.00111	CcSEcCtD
Gemifloxacin—Fatigue—Epirubicin—liver cancer	0.0011	0.00111	CcSEcCtD
Gemifloxacin—Constipation—Epirubicin—liver cancer	0.00109	0.0011	CcSEcCtD
Gemifloxacin—Pain—Epirubicin—liver cancer	0.00109	0.0011	CcSEcCtD
Gemifloxacin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00108	0.00108	CcSEcCtD
Gemifloxacin—Insomnia—Doxorubicin—liver cancer	0.00107	0.00107	CcSEcCtD
Gemifloxacin—Dyspnoea—Doxorubicin—liver cancer	0.00105	0.00106	CcSEcCtD
Gemifloxacin—Somnolence—Doxorubicin—liver cancer	0.00105	0.00106	CcSEcCtD
Gemifloxacin—Gastrointestinal pain—Epirubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Gemifloxacin—Dyspepsia—Doxorubicin—liver cancer	0.00104	0.00105	CcSEcCtD
Gemifloxacin—Decreased appetite—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Gemifloxacin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00102	0.00103	CcSEcCtD
Gemifloxacin—Fatigue—Doxorubicin—liver cancer	0.00102	0.00102	CcSEcCtD
Gemifloxacin—Urticaria—Epirubicin—liver cancer	0.00102	0.00102	CcSEcCtD
Gemifloxacin—Constipation—Doxorubicin—liver cancer	0.00101	0.00102	CcSEcCtD
Gemifloxacin—Pain—Doxorubicin—liver cancer	0.00101	0.00102	CcSEcCtD
Gemifloxacin—Abdominal pain—Epirubicin—liver cancer	0.00101	0.00102	CcSEcCtD
Gemifloxacin—Body temperature increased—Epirubicin—liver cancer	0.00101	0.00102	CcSEcCtD
Gemifloxacin—Gastrointestinal pain—Doxorubicin—liver cancer	0.000967	0.000972	CcSEcCtD
Gemifloxacin—Urticaria—Doxorubicin—liver cancer	0.00094	0.000944	CcSEcCtD
Gemifloxacin—Abdominal pain—Doxorubicin—liver cancer	0.000935	0.000939	CcSEcCtD
Gemifloxacin—Body temperature increased—Doxorubicin—liver cancer	0.000935	0.000939	CcSEcCtD
Gemifloxacin—Asthenia—Epirubicin—liver cancer	0.000917	0.000921	CcSEcCtD
Gemifloxacin—Pruritus—Epirubicin—liver cancer	0.000905	0.000909	CcSEcCtD
Gemifloxacin—Diarrhoea—Epirubicin—liver cancer	0.000875	0.000879	CcSEcCtD
Gemifloxacin—Asthenia—Doxorubicin—liver cancer	0.000849	0.000852	CcSEcCtD
Gemifloxacin—Dizziness—Epirubicin—liver cancer	0.000846	0.000849	CcSEcCtD
Gemifloxacin—Pruritus—Doxorubicin—liver cancer	0.000837	0.000841	CcSEcCtD
Gemifloxacin—Vomiting—Epirubicin—liver cancer	0.000813	0.000816	CcSEcCtD
Gemifloxacin—Diarrhoea—Doxorubicin—liver cancer	0.000809	0.000813	CcSEcCtD
Gemifloxacin—Rash—Epirubicin—liver cancer	0.000806	0.00081	CcSEcCtD
Gemifloxacin—Dermatitis—Epirubicin—liver cancer	0.000805	0.000809	CcSEcCtD
Gemifloxacin—Headache—Epirubicin—liver cancer	0.000801	0.000804	CcSEcCtD
Gemifloxacin—Dizziness—Doxorubicin—liver cancer	0.000782	0.000786	CcSEcCtD
Gemifloxacin—Nausea—Epirubicin—liver cancer	0.000759	0.000763	CcSEcCtD
Gemifloxacin—Vomiting—Doxorubicin—liver cancer	0.000752	0.000755	CcSEcCtD
Gemifloxacin—Rash—Doxorubicin—liver cancer	0.000746	0.000749	CcSEcCtD
Gemifloxacin—Dermatitis—Doxorubicin—liver cancer	0.000745	0.000748	CcSEcCtD
Gemifloxacin—Headache—Doxorubicin—liver cancer	0.000741	0.000744	CcSEcCtD
Gemifloxacin—Nausea—Doxorubicin—liver cancer	0.000703	0.000706	CcSEcCtD
